8-K: Repare Sells RP-3467 Program to Gilead for $30M

Repare Therapeutics Inc. announced the sale of its RP-3467 program assets to Gilead Sciences, Inc. for up to $30 million, increasing the estimated cash payout for its pending acquisition by XenoTherapeutics.

Summary

• Repare Therapeutics Inc. (Repare) entered into an Asset Purchase Agreement with Gilead Sciences, Inc. (Gilead) on December 23, 2025, to sell its RP-3467 program assets.
• The RP-3467 program, currently in clinical development for advanced solid tumors, was acquired by Gilead for an aggregate purchase price of up to $30,000,000 in cash.
• The purchase price consists of a $22,000,000 upfront payment due by December 31, 2025, a holdback amount of up to $3,000,000 payable after one year, and a $5,000,000 transfer completion payment.
• Repare retained assets related to its other programs, including RP-1664 and lunresertib/camonsertib, as well as employee contracts, cash, accounts receivable, real property, and equipment.
• In connection with the sale, Repare and New York University (NYU) entered into a Consent to Assignment, transferring Repare's rights under a July 19, 2018 license agreement to Gilead, for a one-time payment of $250,000 to NYU.
• The upfront payment from Gilead has increased Repare's cash balance, which in turn has increased the estimated cash payment to shareholders in the pending acquisition by XenoTherapeutics, Inc. (Xeno).
• The estimated cash payment per Common Share for the Xeno acquisition is now approximately US$2.20, based on Repare's revised estimate of the Closing Net Cash Amount.

Sentiment

Score: 8

Explanation: The asset sale provides a significant cash infusion, directly increasing the estimated per-share payout for the company's pending acquisition, which is a clear positive for shareholders. It also strategically offloads a development program to a larger player, allowing Repare to focus on its other assets or the upcoming merger.

Positives

• The asset sale provides Repare with up to $30,000,000 in cash, strengthening its financial position.
• The upfront payment of $22,000,000 significantly increases Repare's cash balance, directly benefiting shareholders in the upcoming Xeno acquisition.
• The estimated cash payment to Repare shareholders in the Xeno acquisition has increased to approximately US$2.20 per Common Share.
• Strategic divestment of the RP-3467 program allows Repare to streamline its focus or prepare for the Xeno acquisition, while placing the asset with a major oncology player, Gilead Sciences.

Negatives

• Repare is divesting a clinical-stage precision oncology asset (RP-3467), potentially foregoing future upside if the program proves highly successful under Gilead's ownership.
• The holdback amount of up to $3,000,000 and the $5,000,000 transfer completion payment are contingent on future events, introducing some payment uncertainty.

Risks

• The receipt of the full $30,000,000 purchase price is contingent on the successful completion of the transfer plan and the expiration of a one-year holdback period.
• The consummation of the Asset Sale and the realization of its anticipated benefits are subject to various known and unknown risks and uncertainties.
• The estimated cash payment of US$2.20 per Common Share for the Xeno acquisition is an estimate and could change based on the final cash balance and liabilities at closing.
• General risks associated with clinical development programs, including unexpected safety or efficacy data, lower-than-expected clinical trial enrollment rates, and changes in the regulatory environment.
• Impacts of macroeconomic conditions, including tariffs, trade policies, geopolitical conflicts (Ukraine, Middle East), inflation, and uncertain credit and financial markets, on the company's business and financial position.
• Potential for unexpected litigation or other disputes related to the asset sale or the Xeno acquisition.

Future Outlook

The RP-3467 program will continue its development under Gilead Sciences, Inc., a major player in oncology. Repare Therapeutics will proceed with its pending acquisition by XenoTherapeutics, Inc., with the asset sale improving the cash balance and increasing the estimated per-share payout for its shareholders. Repare will focus on its remaining programs, RP-1664 and lunresertib/camonsertib, until the Xeno acquisition is finalized.

Management Comments

• Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare, stated: 'We are pleased to announce this transaction which combines Gilead's leading expertise in oncology research and development with RP-3467, a potential best-in-class Polθ ATPase inhibitor.'
• Steve Forte also noted: 'This marks the third and most significant portfolio transaction for Repare this year.'

Industry Context

This transaction exemplifies a common strategy in the biotechnology sector where smaller, clinical-stage companies develop promising assets to a certain point and then divest them to larger pharmaceutical companies with greater resources for late-stage development and commercialization. Gilead Sciences, a prominent biopharmaceutical company with significant oncology expertise, is well-positioned to advance RP-3467. For Repare, this divestment, especially in the context of its pending acquisition by XenoTherapeutics, allows it to monetize an asset and enhance shareholder value ahead of its corporate merger.

Comparison to Industry Standards

• The filing does not provide specific comparable company or project data to assess the results against global benchmarks. However, the acquisition of a clinical-stage asset by a major pharmaceutical company like Gilead Sciences is consistent with industry trends of larger players acquiring innovative programs from smaller biotechs.

Corporate Governance

Related Party Transactions

• The Asset Purchase Agreement with Gilead Sciences, Inc. was approved by Repare's board of directors.
• The Consent to Assignment with New York University is related to the RP-3467 program, which was licensed from NYU.
• The filing references the previously announced definitive arrangement agreement with XenoTherapeutics, Inc. and Xeno Acquisition Corp. for the acquisition of Repare's common shares.

Stakeholder Impact

• Shareholders: Will receive a higher estimated cash payment of approximately US$2.20 per Common Share in the pending Xeno acquisition due to the increased cash balance from the asset sale.
• Employees: No transfer of employees to Gilead; Repare remains responsible for all employee-related liabilities.
• Customers/Patients: The RP-3467 program, a potential treatment for advanced solid tumors, will continue its development under Gilead Sciences, potentially benefiting patients.
• New York University: Received a one-time payment of $250,000 and retains potential future milestone payments from Sublicense Income related to the RP-3467 program.

Next Steps

• Gilead Sciences, Inc. is to pay Repare Therapeutics Inc. $22,000,000 by December 31, 2025.
• Repare and Gilead will work towards the successful completion of the RP-3467 program transfer plan, which will trigger a $5,000,000 payment.
• The holdback amount of up to $3,000,000 may become payable to Repare after one year from the Closing Date.
• Repare shareholders will hold a special meeting on January 16, 2026, to vote on the proposed acquisition by XenoTherapeutics, Inc.
• Repare will cooperate with Gilead to transition sponsorship of the RP-3467 Clinical Trial and transfer relevant INDs and assets.

Key Dates

Recommendation

The asset sale is a positive development for Repare Therapeutics shareholders, as it increases the estimated cash payout for the company's pending acquisition by XenoTherapeutics. For existing shareholders, holding the stock is advisable to realize the improved acquisition terms. For new investors, while the increased payout is attractive, the upside is capped by the acquisition price, making it less of a 'buy' for long-term growth and more of an arbitrage opportunity if the stock trades below the estimated US$2.20 per share.

Keywords

Repare Therapeutics, Gilead Sciences, asset sale, RP-3467, polymerase theta inhibitor, oncology, clinical development, advanced solid tumors, synthetic lethality, XenoTherapeutics, merger, acquisition, biotech, pharmaceutical